#lucentis 0.5

[vicky8588]

AMD Drugs Market, Size, Share, Outlook and Growth Opportunities 2021-2028

Market Overview

·         The Global AMD Drugs Market is expected to grow at a CAGR of 6.72% in the forecast period of 2021-2028.

·         Age-related macular degeneration (AMD) is a problem with retina. It happens when a part of the retina called the macula is damaged. AMD lose central vision. Age-related macular degeneration is of two types; dry AMD and wet AMD.

·         Around 80% (8 out of 10) of people who have AMD have the dry form. Dry AMD is when parts of the macula get thinner with age and tiny clumps of a protein called drusen grow. Wet AMD is when new, abnormal blood vessels grow under the retina. These vessels may leak blood or other fluids, causing scarring of the macula. In wet AMD the vision is lost faster as compare to dry AMD.

·         The global AMD drugs market was worth XX billion in 2018 and is forecasted to reach XX billion by 2026, at a CAGR of XX% during the forecast period.

 Download free sample: https://www.datamintelligence.com/download-sample/amd-drugs-market

 Market Dynamics

·         The rising prevalence of age-related macular degeneration is one of the factors fueling the global AMD drugs market.

·         Age-related macular degeneration (AMD), is a leading cause of vision loss in Americans 60 and older.

·         According to the World Health Organization (WHO), 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050.

·         The number of people living with macular degeneration is expected to reach 196 million worldwide by 2020 and increase to 288 million by 2040.

·         According to the Centers for Disease Control and Prevention, age is a prominent risk factor for age-related macular degeneration. The risk of getting advanced age-related macular degeneration increases from 2% for those ages 50-59 to nearly 30% for those over the age of 75.

·         According to Centers for Disease Control and Prevention, the prevalence of AMD in the UK among people aged 50 years or over is 2.4% in 2015, and has been increased to 4.8% in people aged 65 years or over, and 12.2% in people aged 80 years or over.

 Market Segmentation Analysis

·         Based on product type the global market for AMD drugs is broadly segmented as by wet AMD, and dry ADM.

·         Currently, wet AMD is the dominant segment, and it accounts for approximately XX% of the market, due to the increasing regulatory approval for wet AMD.

·         For instance, in August 2018, Regeneron Pharmaceuticals, Inc. have received the U.S. Food and Drug Administration (FDA) approval for supplemental Biologics License Application (sBLA) for EYLEA (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).

·         In October 2016, Roche, has received the U.S. Food and Drug Administration (FDA) approval the Lucentis (ranibizumab injection) 0.5 mg prefilled syringe (PFS), it is a new method of administering the medicine. The Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related macular degeneration (AMD) and macular edema after retinal vein occlusion (RVO).

 Geographical Analysis

·         The global AMD drugs market is segmented into North America, Europe, Asia Pacific, South America, and ROW.

·         North America is dominating the global AMD drugs market, due to the increasing acceptance for investigation of pipeline product, and regulatory approval of AMD drugs, which is fueling the market growth.

·         For instance, in January 2018, Pixium Vision, has received the approval from the US Food and Drug Administration (FDA) to begin the clinical feasibility study for PRIMA, Pixium Vision’s new-generation miniaturized wireless photovoltaic sub-retinal implant, in patients with Atrophic Dry Age-related Macular Degeneration (AMD).

·         In January 2017, Genentech have received FDA approval for Lucentis as a treatment for patients with choroidal neovascularization (CNV) resulting from myopic macular degeneration (MMD), also known as myopic degeneration. Lucentis is the first FDA-approved anti-VEGF therapy to treat myopic CNV (mCNV) in the U.S.

 Competitive Analysis

·         The increasing pipeline product and strategic alliance between companies for AMD drugs are one of the critical factor driving the global AMD drugs market.

·         For instance, in November 2018, Ophthotech Corporation, is on Phase 2a safety trial of Zimura (avacincaptad pegol), for patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD.

·         In April 2018, Novartis announced is on Phase III trial for brolucizumab (RTH258) data in neovascular age-related macular degeneration (AMD) from a pre-specified secondary analysis of HAWK and HARRIER trials.

·         In August 2017, Ophthotech Corporation was on Phase 3 clinical trial for Fovista (pegpleranib) anti-PDGF therapy in combination with Eylea (aflibercept) or Avastin® (bevacizumab) anti-VEGF therapy compared to Eylea or Avastin monotherapy for the treatment of wet age-related macular degeneration (AMD).

·         In June 2015, Bayer HealthCare collaborated with Johns Hopkins University for five years to jointly develop new therapies targeting retinal diseases. Bayer has partnered with Johns Hopkins’ Wilmer Eye Institute to discover and develop drugs for back-of-the-eye diseases that include age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt’s disease, and retinal vein occlusion (RVO).

 View full report: https://www.datamintelligence.com/research-report/amd-drugs-market

 Enquiry before buying: https://www.datamintelligence.com/enquiry/amd-drugs-market

 About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

 For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: [phone]

Website: www.datamintelligence.com

#wet mad #dry mad #lusicntis #intravenous

[lupine-publishers-tooaj]

Lupine Publishers | Guide Lines for Wet AMD Treatment

Lupine Publishers | Trends in Ophthalmology Open Access Journal

Abstract

Purpose: To give practical guide lines for the management of neovascular AMD

Methods: To evaluate the above-mentioned item based on recently published data.

Results: Although many therapeutic modalities have been employed for neovascular AMD treatment, yet anti-VEGFs are still the best line of treatment.

Conclusion: Although anti-VEGFs are up till now the best line of treatment for nAMD yet a knowledge of how to use them with or without other modalities is very important to get the best therapeutic results.

Keywords: nAMD; Anti-VEGFs

Introduction

Many therapeutic modalities have been employed for neovascular AMD which includes:

I. Macular laser photocoagulation [Macular Photocoagulation Study (MPS) can result in preventing severe loss of vision in about 50 percent of treated patients with extra/ juxta foveal CNV, with about 50 percent of patients developing recurrent choroidal neovascular membrane (CNVM).

II. Photodynamic therapy (PDT) with verteporfin acts via activating a photosensitizing dye within the pathologic vessels by infrared laser leading to occlusion of choroidal new vessels with minimal damage to the retina. PDT can prevent 3-line vision loss in about 49 to 77 percent of treated patients but seldom improves vision [1].

III. With the establishment of VEGF as the main cause for the development and progression of neovascularization, novel agents to block them and thereby preventing further progression was sought for. With the advent of anti-VEGF agents, the treatment for neovascular AMD has completely changed, with dramatic outcomes.

Anti-VEGFs

The inclusion of ranibizumab, a nonspecific VEGF inhibitor further refined the results of anti-VEGF therapy for neovascular AMD [2]. The MARINA study evaluated the effect of ranibizumab injection in patients with minimally classic or occult CNV. The conclusion of Marina study was that monthly IVL injection for 2 years prevented vision loss and improved mean VA in patients with minimally classic / occult CNV secondary to AMD. The conclusion of the ANCHOR trial was that Lucentis was superior to PDT as treatment of predominantly classic NAMD [3- 9]. The Comparison of AMD Treatments Trial Study (CATT study) trial was primarily designed to determine if bevacizumab works as well as ranibizumab in terms of visual outcomes (a difference of <5 letters), and also to identify any safety differences between the two drugs.

Visual outcome results:

When comparing ranibizumab monthly to bevacizumab monthly, the CATT study demonstrated no difference between the two drugs, with patients in both groups gaining more than 8 letters on the eye chart on average over the course of a year and the results were maintained over 2 years.

Safety Outcomes

The rate of ocular infection following injection of medication was similar with the two drugs [10].

A similar head to head comparison trial between the two drugs was the alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularization [IVAN]: 1year results concluded similar efficacy of both drugs [11].

Treatment Protocols: Primarily Designed for AMD

Ranibizumab: As-needed Regimen The Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intraocular Ranibizumab [PrONTO] Study: In this study patients received 3 consecutive monthly injections of 0.5 mg ranibizumab and were then followed monthly and retreated if there was an increase in OCT central retinal thickness [CRT] of at least 100 microns or a loss of best-corrected ETDRS VA of 5 letters or more. In the PrONTO study, VA outcomes were comparable with those reported in ranibizumab phase III clinical studies, but with fewer intravitreal injections [12]. The Sailor [13], Sustain [14] and Horizon [15] trials are other as needed regime studies. Overall, these studies support frequent follow-up and individualized retreatment to achieve the best visual acuity gains with the as-needed treatment regimen.

Ranibizumab: Treat-and-Extend Regimen:

Treat-and-extend dosing regimen involves increasing intervals between treatment up to 10 weeks as long as no fluid is present on OCT. If fluid is present, the interval between treatments is shortened. Oubraham found that at one-year, mean gain in VA was greater in the treat and-extend group than in the as-needed group [+10.8 versus+2.3 letters, resp.]. Eyes in the treat-and-extend group received significantly more mean injections [7.8 versus 5.2] [16]. Similar trials were also done with Bevcizumab with similar results [17-25].

Aflibercept as Compared to Other Anti-VEGFs

A. Aflibercept is a soluble decoy receptor produced by fusing all-human DNA sequences of the second immunoglobulin domain of human VEGFR1 and the third immunoglobulin domain of human VEGFR2, which then fused to the Fc region of human IgG1.2. The intravitreal half-life of aflibercept is 4.7 days in rabbit eyes, which is longer than ranibizumab [2.9 days] and comparable with bevacizumab [4.3 days].

B. The combined high affinity and longer half-life has led to a calculated duration of effect of a single intravitreal injection of 2 mg aflibercept of 48-83 days. Monthly treatment with aflibercept has been shown to improve the vision in exudative AMD in 2 clinical trials. VIEW [VEGF Trap-Eye: Investigation of Efficacy and Safety in wet AMD] 1 and View 2 showed that, at 1 year, aflibercept treatment [0.5, 2 mg monthly, or 2 mg every 2 months after three initial monthly doses] was non-inferior and clinically equivalent to ranibizumab [0.5 mg] given monthly [26].

C. Aflibercept therapy appears to be beneficial in a subset of patients with neovascular age-related macular degeneration who exhibit recurrent or resistant intra-retinal or subretinal fluid following multiple injections with either bevacizumab or ranibizumab [27].

Anatomical Measures as Predictors of Visual Outcomes in Ranibizumab-Treated Eyes with Neovascular Age- Related Macular Degeneration:

a) First and foremost, an initial anatomical [according to FFA and/or OCT analyses] or visual improvement after three monthly ranibizumab injections does not guarantee longterm success. For eyes with FFA lesion activity at Month 3, CFT>/=200mm at Month 3, and qualitative OCT activity at Months 2 and Month 3 the average BCVA gain from 3 monthly loading doses of ranibizumab was lost after switching to quarterly dosing [every 3 months], and eyes lost vision compared with baseline at Months 12 and 24.

b) Second, it appears that the longer anatomical improvements were maintained [according to FFA or OCT], the more likely it was that the BCVA benefits of ranibizumab persisted on a quarterly dosing regimen. Eyes with inactive FFA lesions at Month 5 or inactive OCT lesions at Month 5 or Month 8 were much more likely to maintain their BCVA gains.

c) While a surprisingly low number of eyes demonstrated inactive FFA lesions after 3 loading doses of ranibizumab (i.e., 10% at Month 3), eyes with a dry FFA showed the strongest association with BCVA outcomes at Months 12 and 24. At the same 3-month time point, 60% of evaluated eyes were dry on qualitative OCT grading. This disparity may result from the sampling error introduced by having only two scans available for grading (rather than all 6 radial line scans available from a Stratus macular thickness map or the greatly increased sample size of currently available spectral-domain OCT devices). It is also known that an effective RPE pump sometimes keeps the retina dry and gives a “dry” OCT reading, despite active CNV leakage [28].

Comparison of Spectral-Domain and Time-Domain Optical Coherence Tomography in the Detection of Neovascular Age- Related Macular Degeneration Activity:

a. With high-resolution volumetric SD-OCT imaging, physicians are capable of detecting signs of exudative AMD activity more precisely. Time domain platforms are less likely to identify active exudative disease activity; this could potentially lead to undertreatment of active neovascular AMD.

b. Both volumetric and raster scans collect data in the same way, via parallel B-scans. The important difference being that volumetric scanning includes more parallel B-scans, in a denser array, providing higher resolution and the ability to render a three-dimensional image. For example, with the Cirrus platform, the 5-line raster algorithm uses only 5 B-scans compared with 128 B-scans used with the volumetric scan [29-30] (Figure 1).

c. Some areas of exudative activity that oriented more vertically were better visualized with radially oriented SD imaging compared with the more traditional horizontal raster scanning patterns [30] (Figure 2).

If after 3 loading doses of Ranibizumab the CNV activity disappeared but the visual acuity did not improve as expected, this might be either due to a disrupted IS/OS line or a thick CNV membrane. In conclusion Visual acuity was most improved when the disrupted IS/OS line was better restored, and CNV thickness was more decreased [31] (Figure 3).

Correlation of Spectral Domain Optical Coherence Tomography Characteristics with Visual Acuity in Eyes with Sub-foveal Scarring After Treatment for Wet Age-Related Macular Degeneration

In a case series, visual acuity in cases of sub foveal scarring was affected mainly by the integrity of the IS/OS and external limiting membrane lines [32] (Figure 4).

Spectral domain OCT scans of patients with sub foveal scarring:

A. Thin fovea with subfoveal scarring, VA: Counting fingers.

B. Intact IS/OS junction (arrowhead) and ELM (arrow) in fovea, VA: 20/32.

C. Normal foveal thickness with no IS/OS or ELM seen, VA: Counting fingers.

D. Intact ELM at fovea, with intact IS/OS near fovea, VA: 20/40.

E. Foveal cystoid degeneration, VA: 20/800.

F. Cystoid degeneration with disrupted IS/OS within central 1,000 mm, but intact near fovea, VA: 20/80 [32].

Response 0f Pigment Epithelial Detachments to Intravitreal Aflibercept among Patients with Treatment-Resistant Neovascular Age-Related Macular Degeneration

Three PED types were identified on OCT; hollow, solid and mixed. The hollow type showed the best response to aflibercept treatment while the solid type was the worst in response (Figure 5).

a) Hollow: are hypo reflective and contain fluid exudate

b) Solid: hyper reflective and represents fibrinous leakage or fibrovascular proliferation, suggesting active neovascularization.

c) Mixed:

i) Vision loss associated with PEDs seems to be largely nonreversible , even with structural reduction of the lesion.

ii) Retinal pigment epithelium tears may complicate treatment of PEDs during treatment with intravitreal anti-VEGF therapy. Larger vascularized PEDs that have a higher intraluminal pressure are at a significantly greater risk of producing RPE tears after anti- VEGF therapy (especially in the early stages of ttt), with acute vision loss [33].

Unfavorable Anatomical Response to Anti VEGFs

I. Some patients, however, have a good initial response to Avastin & Lucentis with resolution of fluid, but then later become resistant to further treatment and develop recurrent exudation with vision loss. The mechanism of this resistance to treatment with these drugs is not known, but one possibility is tolerance or tachyphylaxis, manifested by a decreased response over time to repeated treatment with a medication. Tachyphylaxis sometimes can be reversed by increasing the dose or halting therapy for a period of time before reinstating the same treatment.

II. Aflibercept therapy as mentioned above, appears to be beneficial in a subset of patients with neovascular age-related macular degeneration who exhibit recurrent or resistant intraretinal or subretinal fluid following multiple injections with either bevacizumab or ranibizumab [27].

Response of Type 3 Neovascularization to Anti-VEGF Treatment

a) The CME and sub-RPE fluid associated with Type 3 neovascularization resolve briskly with intravitreal anti-VEGF therapy, typically after only one or two injections.

b) A recent, longitudinal prospective study examining the response of Type 3 lesions to anti-VEGF therapy demonstrated that all eyes had stable or improved vision at 3 years of follow-up after a mean of 9.4 injections during that time. The visual prognosis was excellent [34].

Combination Therapies for Wet AMD

Role of Additional Dexamethasone for the Management of Persistent or Recurrent Neovascular Age Related Macular Degeneration Under Ranibizumab Treatment

a) The efficacy of a combination therapy of intravitreal ranibizumab together with a dexamethasone implant in comparison with ranibizumab monotherapy in persistent or recurrent neovascular age-related macular degeneration was studied and it was found that combined therapy delays retreatment in patients with persistent/recurrent neovascular age-related macular degeneration and an overall reduction in required ranibizumab retreatments compared with ranibizumab monotherapy with consistent functional outcomes. [35].

b) The expectations on the improved effect of a combination therapy lie on the multifactorial pathogenesis of nAMD involving angiogenesis and inflammation. As CNV persist under monotherapy, a combined approach seems to be reasonable to decelerate disease progression. Corticosteroids act because of their anti-inflammatory, antiangiogenic, and antiedematous effects [36-38]. Hence, additional corticosteroids seem to have the ability to target chronic inflammation when combined with anti-VEGF. In addition, a decrease in effect during an anti- VEGF monotherapy has been reported, and desensitization of tachyphylaxis by adding corticosteroids in chronic CNV was suggested [39].

Anti- VEGF Combined with Photodynamic Therapy

The combination has an additive or synergistic effect; PDT targets the vascular component Anti-VEGF targets the mediators of the angiogenic cascade and counteracts up-regulation of angiogenic factors that occur after PDT treatment. The combination causes reduction of re-treatment rate BUT may not achieve equivalent visual acuity outcomes [40-42].

Avastin Triple Therapy

a. The aim of this treatment is to combine Avastin with PDT and Dexamethasone. First PDT Light dose 42j/cm is delivered in 70 sec then after 16h. Intravitreal injection of 800mcg dexamethasone plus 1.5mg Avastin are given.

b. Triple therapy in one study was found to result in a good VA outcome with lower cost compared to repeated injections. Other studies, however, failed to show any benefit of the triple therapy as compared to anti-VEGF monotherapy [43-44]

 https://lupinepublishers.com/ophthalmology-journal/pdf/TOOAJ.MS.ID.000121.pdf

https://lupinepublishers.com/ophthalmology-journal/fulltext/guide-lines-for-wet-amd-treatment.ID.000121.php

For more Lupine Publishers Open Access Journals Please visit our website: https://lupinepublishersgroup.com/

For more Trends in Ophthalmology Please Click

Here: https://lupinepublishers.com/ophthalmology-journal/

To Know more Open Access Publishers Click on Lupine Publishers

Follow on Linkedin : https://www.linkedin.com/company/lupinepublishers Follow on Twitter   :  https://twitter.com/lupine_online

#Lupinepublishers #optics #ophthalmic history

[healthcare00897]

Macular Edema Treatment Market Boosting The Growth: Market Dynamics And Trends, Efficiencies Forecast

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an oval-shaped pigmented area near the center of retina. This blister causes the macula to swell and thicken that causes distortion of vision. Although macular edema has numerous causes, the most common cause is diabetes. Other causes include, age-related macular degeneration, replacement of lenses in treatment of cataract, chronic uveitis and intermediate uveitis, blockage of vein in the retina, and congenital diseases including retinitis pigmentosa and retinoschisis. Symptoms of macular edema include blurry or wavy vision near or in the center of field of vision. The disease is diagnosed by performing tests such as visual acuity test, dilated eye exam, fluorescein angiogram, optical coherence tomography, and Amsler grid.

Get Exclusive Sample Report at: http://bit.ly/2IgbA7y

Macular Edema Treatment Market: Drivers

Increasing number of pipeline studies is expected to drive the macular edema treatment market growth. For instance, in April 2018, University of California, Davis, in collaboration with IRIDEX Corporation, initiated phase 3 clinical trial for Micropulse Laser Treatment to evaluate micropulse for suppression of diabetic macular edema (pulse). The primary aim of the study is to determine whether the micropulse laser treatment in eyes with good visual acuity will improve or stabilize vision loss due to the complications of diabetic macular edema. The study is expected to be completed by December 2020.

Furthermore, increasing approval for new diabetic macular edema (DME) therapies is expected to propel growth for the macular edema treatment market. For instance, in March 2018, U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS) for diabetic macular edema and diabetic retinopathy. Lucentis 0.3 mg PFS is the first syringe prefilled with an anti-vascular endothelial growth factor (VEGF) agent. Moreover, in 2016 U.S.FDA approved Lucentis 0.5 mg PFS, which is intended for use in the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularisation (mCNV).

However, lack of awareness of diabetic eye diseases among the patients with diabetes is expected to hinder the macular edema treatment market growth.

Macular Edema Treatment Market: Regional Analysis

On the basis of region, the global macular edema treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to account for the largest market share in the macular edema treatment market, owing to increasing prevalence of diabetic macular edema in this region. For instance, according to American Journal of Managed Care (AJMC), in 2016, the prevalence rate of diabetic macular edema was 45.3% in North America.

Moreover, in 2013, as per National Center for Biotechnology Information (NCBI), around 98 million individuals reported for diabetic retinopathy (DR) and 21 million individual reported for diabetic macular edema (DME) worldwide.

Furthermore, increasing product approvals for the treatment of macular edema is expected to boost growth of the macular edema treatment market in Europe. For instance, in 2015, the European Commission approved Eylea (aflibercept) for the treatment of patients with macular edema secondary to retinal vein occlusion. Bayer HealthCare and Regeneron collaborated to develop Eylea. Bayer HealthCare has exclusive marketing rights to the product outside the U.S.

Ask For Discount Before Purchasing This Business Report @ http://bit.ly/31wHqo1

Key players operating in the macular edema treatment market include, Novartis International AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Pfizer Inc. Bayer AG, Aerpio Therapeutics, Inc., Biomar Microbial Technologies, Antisense Therapeutics Limited, Coherus BioSciences, and Bausch & Lomb Incorporated.

Macular Edema Treatment Market Taxonomy

By Disease Type

   Diabetic Macular Edema

   Cystoid Macular Edema

By Drug Class

   Anti-Vascular endothelial growth factor (VEGF) injections

       Avastin

       Eylea

       Lucentis

  Anti-inflammatory Medication

       Nonsteroidal anti-inflammatory drugs (NSAIDs)

      Corticosteroid

           Ozurdex

           Retisert

           Iluvien

By End User

   Hospitals

   Ophthalmic Clinics

   Research Institutes

By Region

   North America

   Europe

   Asia Pacific

   Latin America

   Middle East

   Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: [phone]

Email: [email protected]

#Macular Edema Treatment Market Macular Edema Treatment Trends Macular Edema Treatment Share Macular Edema Treatment Trends

[expertofmarketinsights-blog]

Macular Edema Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an oval-shaped pigmented area near the center of retina. This blister causes the macula to swell and thicken that causes distortion of vision. Although macular edema has numerous causes, the most common cause is diabetes. Other causes include, age-related macular degeneration, replacement of lenses in treatment of cataract, chronic uveitis and intermediate uveitis, blockage of vein in the retina, and congenital diseases including retinitis pigmentosa and retinoschisis. Symptoms of macular edema include blurry or wavy vision near or in the center of field of vision. The disease is diagnosed by performing tests such as visual acuity test, dilated eye exam, fluorescein angiogram,optical coherence tomography, and Amsler grid. Click To Read More On Macular Edema Treatment Market.

Macular Edema Treatment Market: Drivers

Increasing number of pipeline studies is expected to drive the macular edema treatment market growth. For instance, in April 2018, University of California, Davis, in collaboration with IRIDEX Corporation, initiated phase 3 clinical trial for Micropulse Laser Treatment to evaluate micropulse for suppression of diabetic macular edema (pulse). The primary aim of the study is to determine whether the micropulse laser treatment in eyes with good visual acuity will improve or stabilize vision loss due to the complications of diabetic macular edema. The study is expected to be completed by December 2020.

Furthermore, increasing approval for new diabetic macular edema (DME) therapies is expected to propel growth for the macular edema treatment market. For instance, in March 2018, U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS) for diabetic macular edema and diabetic retinopathy. Lucentis 0.3 mg PFS is the first syringe prefilled with an anti-vascular endothelial growth factor (VEGF) agent. Moreover, in 2016 U.S.FDA approved Lucentis 0.5 mg PFS, which is intended for use in the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularisation (mCNV).

Macular Edema Treatment Market: Regional Analysis

On the basis of region, the global macular edema treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to account for the largest market share in the macular edema treatment market, owing to increasing prevalence of diabetic macular edema in this region. For instance, according to American Journal of Managed Care (AJMC), in 2016, the prevalence rate of diabetic macular edema was 45.3% in North America.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2494

Moreover, in 2013, as per National Center for Biotechnology Information (NCBI), around 98 million individuals reported for diabetic retinopathy (DR) and 21 million individual reported for diabetic macular edema (DME) worldwide.

Furthermore, increasing product approvals for the treatment of macular edema is expected to boost growth of the macular edema treatment market in Europe. For instance, in 2015, the European Commission approved Eylea (aflibercept) for the treatment of patients with macular edema secondary to retinal vein occlusion. Bayer HealthCare and Regeneron collaborated to develop Eylea. Bayer HealthCare has exclusive marketing rights to the product outside the U.S.

Competitive Analysis

Key players operating in the macular edema treatment market include, Novartis International AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Pfizer Inc. Bayer AG, Aerpio Therapeutics, Inc., Biomar Microbial Technologies, Antisense Therapeutics Limited, Coherus BioSciences, and Bausch & Lomb Incorporated.

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: [phone] Email: [email protected]

#Macular Edema Treatment Market #Macular Edema Treatment Market Size #Macular Edema Treatment Market Share #Macular Edema Treatment Market Outlook

[healthcare00897]

Macular Edema Treatment Market Showing Compound Annual Growth Rate And Forecast Till 2026

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an oval-shaped pigmented area near the center of retina. This blister causes the macula to swell and thicken that causes distortion of vision. Although macular edema has numerous causes, the most common cause is diabetes. Other causes include, age-related macular degeneration, replacement of lenses in treatment of cataract, chronic uveitis and intermediate uveitis, blockage of vein in the retina, and congenital diseases including retinitis pigmentosa and retinoschisis. Symptoms of macular edema include blurry or wavy vision near or in the center of field of vision. The disease is diagnosed by performing tests such as visual acuity test, dilated eye exam, fluorescein angiogram, optical coherence tomography, and Amsler grid.

Get Exclusive Sample Report at: http://bit.ly/2IgbA7y

Macular Edema Treatment Market: Drivers

Increasing number of pipeline studies is expected to drive the macular edema treatment market growth. For instance, in April 2018, University of California, Davis, in collaboration with IRIDEX Corporation, initiated phase 3 clinical trial for Micropulse Laser Treatment to evaluate micropulse for suppression of diabetic macular edema (pulse). The primary aim of the study is to determine whether the micropulse laser treatment in eyes with good visual acuity will improve or stabilize vision loss due to the complications of diabetic macular edema. The study is expected to be completed by December 2020.

Furthermore, increasing approval for new diabetic macular edema (DME) therapies is expected to propel growth for the macular edema treatment market. For instance, in March 2018, U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS) for diabetic macular edema and diabetic retinopathy. Lucentis 0.3 mg PFS is the first syringe prefilled with an anti-vascular endothelial growth factor (VEGF) agent. Moreover, in 2016 U.S.FDA approved Lucentis 0.5 mg PFS, which is intended for use in the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularisation (mCNV).

However, lack of awareness of diabetic eye diseases among the patients with diabetes is expected to hinder the macular edema treatment market growth.

Macular Edema Treatment Market: Regional Analysis

On the basis of region, the global macular edema treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to account for the largest market share in the macular edema treatment market, owing to increasing prevalence of diabetic macular edema in this region. For instance, according to American Journal of Managed Care (AJMC), in 2016, the prevalence rate of diabetic macular edema was 45.3% in North America.

Moreover, in 2013, as per National Center for Biotechnology Information (NCBI), around 98 million individuals reported for diabetic retinopathy (DR) and 21 million individual reported for diabetic macular edema (DME) worldwide.

Furthermore, increasing product approvals for the treatment of macular edema is expected to boost growth of the macular edema treatment market in Europe. For instance, in 2015, the European Commission approved Eylea (aflibercept) for the treatment of patients with macular edema secondary to retinal vein occlusion. Bayer HealthCare and Regeneron collaborated to develop Eylea. Bayer HealthCare has exclusive marketing rights to the product outside the U.S.

Ask For Discount Before Purchasing This Business Report @ http://bit.ly/31wHqo1

Key players operating in the macular edema treatment market include, Novartis International AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Pfizer Inc. Bayer AG, Aerpio Therapeutics, Inc., Biomar Microbial Technologies, Antisense Therapeutics Limited, Coherus BioSciences, and Bausch & Lomb Incorporated.

Macular Edema Treatment Market Taxonomy

By Disease Type

   Diabetic Macular Edema

   Cystoid Macular Edema

By Drug Class

   Anti-Vascular endothelial growth factor (VEGF) injections

       Avastin

       Eylea

       Lucentis

  Anti-inflammatory Medication

       Nonsteroidal anti-inflammatory drugs (NSAIDs)

      Corticosteroid

           Ozurdex

           Retisert

           Iluvien

By End User

   Hospitals

   Ophthalmic Clinics

   Research Institutes

By Region

   North America

   Europe

   Asia Pacific

   Latin America

   Middle East

   Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: [phone]

Email: [email protected]